Objective To explore the relationship between heat-shock protein 70-2 gene +1267A/G polymorphism(HSP70-2 gene +1267A/G polymorphism) and serum level of high sensitivity C-reactive protein(Hs-CRP) in patients with coro...Objective To explore the relationship between heat-shock protein 70-2 gene +1267A/G polymorphism(HSP70-2 gene +1267A/G polymorphism) and serum level of high sensitivity C-reactive protein(Hs-CRP) in patients with coronary artery disease(CAD).Methods Serum Hs-CRP level and HSP70-2 gene +1267A/G polymorphism were detected in 185 patients with CAD.HSP70-2 gene +1267A/G polymorphism was screened by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP).Results The genotype distribution of the HSP70-2 gene +1267A/G polymorphism was as follows: AA was in 24 of 185 patients(12.97%),AG in 93 of 185 patients(50.27%) and GG in 68 of 185 patients(36.76%).Patients with GG、AG subtype had higher Hs-CRP levels compared with carriers of the AA subtype(4.5±1.8mg/L,3.2±1.2mg/L and 2.7±1.1mg/L,respectively,P<0.05).Among patients who had Hs-CRP >3mg/L,GG,and AG gene subtypes had higher percentage than A allele homozygotes(92.6%,74.2% and 45.8%,respectively.χ2=17.75,28.04,P<0.05).Conclusions This study indicated G allele of HSP70-2 gene +1267A/G polymorphism may be an independent risk factor in systemic inflammation with stable CAD.展开更多
To investigate the therapeutic efficacy of compound immunotherapy of tumor deri ved heat shock protein 70 (HSP70) and interleukin 2 (IL 2) on tumor bearing m ice, and to provide reference for translating this stra...To investigate the therapeutic efficacy of compound immunotherapy of tumor deri ved heat shock protein 70 (HSP70) and interleukin 2 (IL 2) on tumor bearing m ice, and to provide reference for translating this strategy to human cancer Methods Cell culture, techniques for protein extraction and purification, SDS PAGE, Wes tern blot and capillary electrophoresis for HSP70 detection and purity analysis, and animal experiments were used Mice were treated with HSP70 5 or 10 μg an d IL 2 50 kU, 100 kU or 2 kU (maintaining dosage) at pre viously designated intervals Results Both the mono administration of either HSP70 or IL 2 and the compound immunoth erapy of HSP70 and IL 2 obviously inhibited the growth of the implanted tumor a nd prolonged the life span of the mice to different extents However, long peri ods of tumor free suvival (over 90 days) were demonstrated only in HSP70 10 μg group, HSP70 10 μg IL 2 50 kU group, and HSP70 10 μg IL 2 100 kU group (4 0%, 40%, 60% respectively) On the other hand, none of the mice in the rest gr oups achieved long term survival Statistical significance was apparent in com parison with the groups without long period survival ( P <0 025-0 05) Conclusion Our research revealed that tumor derived HSP70 immunotherapy was much more effe ctive than IL 2 alone And in compound immunotherapy, HSP70 was the main factor in delaying or eradicating the tumors The proper combination of HSP70 and IL 2 (10 μg HSP70 and 100 kU IL 2 in this experimental mouse model) clea rly enhanced the immunotherapy efficacy which indicated that the specific immuno therapy as a main part of tumor immunotherapy assisted by cytokine immunotherapy would be a promising strategy in cancer treatment展开更多
文摘Objective To explore the relationship between heat-shock protein 70-2 gene +1267A/G polymorphism(HSP70-2 gene +1267A/G polymorphism) and serum level of high sensitivity C-reactive protein(Hs-CRP) in patients with coronary artery disease(CAD).Methods Serum Hs-CRP level and HSP70-2 gene +1267A/G polymorphism were detected in 185 patients with CAD.HSP70-2 gene +1267A/G polymorphism was screened by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP).Results The genotype distribution of the HSP70-2 gene +1267A/G polymorphism was as follows: AA was in 24 of 185 patients(12.97%),AG in 93 of 185 patients(50.27%) and GG in 68 of 185 patients(36.76%).Patients with GG、AG subtype had higher Hs-CRP levels compared with carriers of the AA subtype(4.5±1.8mg/L,3.2±1.2mg/L and 2.7±1.1mg/L,respectively,P<0.05).Among patients who had Hs-CRP >3mg/L,GG,and AG gene subtypes had higher percentage than A allele homozygotes(92.6%,74.2% and 45.8%,respectively.χ2=17.75,28.04,P<0.05).Conclusions This study indicated G allele of HSP70-2 gene +1267A/G polymorphism may be an independent risk factor in systemic inflammation with stable CAD.
文摘To investigate the therapeutic efficacy of compound immunotherapy of tumor deri ved heat shock protein 70 (HSP70) and interleukin 2 (IL 2) on tumor bearing m ice, and to provide reference for translating this strategy to human cancer Methods Cell culture, techniques for protein extraction and purification, SDS PAGE, Wes tern blot and capillary electrophoresis for HSP70 detection and purity analysis, and animal experiments were used Mice were treated with HSP70 5 or 10 μg an d IL 2 50 kU, 100 kU or 2 kU (maintaining dosage) at pre viously designated intervals Results Both the mono administration of either HSP70 or IL 2 and the compound immunoth erapy of HSP70 and IL 2 obviously inhibited the growth of the implanted tumor a nd prolonged the life span of the mice to different extents However, long peri ods of tumor free suvival (over 90 days) were demonstrated only in HSP70 10 μg group, HSP70 10 μg IL 2 50 kU group, and HSP70 10 μg IL 2 100 kU group (4 0%, 40%, 60% respectively) On the other hand, none of the mice in the rest gr oups achieved long term survival Statistical significance was apparent in com parison with the groups without long period survival ( P <0 025-0 05) Conclusion Our research revealed that tumor derived HSP70 immunotherapy was much more effe ctive than IL 2 alone And in compound immunotherapy, HSP70 was the main factor in delaying or eradicating the tumors The proper combination of HSP70 and IL 2 (10 μg HSP70 and 100 kU IL 2 in this experimental mouse model) clea rly enhanced the immunotherapy efficacy which indicated that the specific immuno therapy as a main part of tumor immunotherapy assisted by cytokine immunotherapy would be a promising strategy in cancer treatment
